Feb 17 (Reuters) - Drug developer Compass Pathways said on Tuesday its psilocybin-based depression therapy reduced the severity of symptoms in a late-stage study, sending its shares up nearly 30%. The ...

Compass Pathways (CMPS) added ~20% in the premarket on Tuesday after the U.K.-based biotech announced that its psychedelic therapy COMP360 reached the primary endpoint in a late-stage trial for ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

The latest readout, from the COMP006 study, showed that two doses of the highest, 25mg dose of COMP360, given in a controlled environment with psychological support from a trained therapist, were ...

LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, ...

LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...

Research will take place in the UK, including at the newly opened Centre for Mental Health Research and Innovation in London, developed in partnership with South London and Maudsley NHS Foundation ...

Shares of Compass Pathways PLC climbed on Friday after the U.S.-listed healthcare group announced a successful follow-up study of a psychedelic drug used to treat major depression in cancer patients.

LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...